Roche, Catalent and Novo Nordisk

Roche comes out against allowing takeover of drug manufacturer Catalent
The CEO of pharmaceuticals giant Roche said authorities should block the takeover of contract drug manufacturer Catalent by Novo Nordisk's controlling shareholder, as it could hit competition in the booming weight-loss drug industry.
Roche CEO says Novo's Catalent buyout 'could be a problem' for smaller drugmakers
The groups behind the letter alleged that Novo Nordisk’s plant purchases could hinder not only the Danish drugmaker’s chief commercial rival, Eli Lilly, but also companies like Viking Therapeutics, Pfizer, Roche and AstraZeneca, who are working on their own metabolic offerings.
Roche CEO Urges FTC to Block Novo Nordisk's Acquisition of Catalent
Roche CEO Urges FTC to Block Novo Nordisks Acquisition of Catalent Roches CEO, Thomas Schinecker, has called on authorities to prevent Novo Nordisks controlling shareholder, Novo Holdings, from acquiring contract
Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition
Roche reported a 9% increase in third-quarter sales, driven by strong performance from Ocrevus and Vabysmo. Roche also raised concerns over the Catalent acquisition.
Roche Beats Q3 Sales Estimates as CEO Voices Opposition to Novo Holdings’ Catalent Buyout
Jefferies analyst Peter Welford noted that Roche’s pharma group came just slightly ahead of consensus expectations, driven by strong performance of its multiple sclerosis therapy Ocrevus and eye injection Vabysmo.
Roche Comes Out Against Clearing Takeover of Drug Manufacturer Catalent
FRANKFURT (Reuters) - The CEO of pharmaceuticals giant Roche has urged authorities to block the takeover of contract drug manufacturer Catalent by Novo Nordisk's controlling shareholder, citing harm to industry peers. "It's not a problem for us ...
Roche CEO says antitrust regulators should block Catalent sale to Novo Foundation
The CEO of Swiss pharmaceuticals behemoth Roche (OTCQX:RHHBY) said he believes antitrust regulators should not allow Novo Nordisk Foundation's to purchase Catalent (NYSE:CTLT). "It's not a problem for us,
Zacks.com on MSN3h
CTLT Stock Falls as Potential Hindrance to NVO Buyout Deal Increases
Catalent stock faces uncertainty as several pharma companies voice concern about potential limited competition following the ...
devdiscourse6h
Pharmaceutical Shifts and Health Innovations: A Global Perspective
Current health news covers Roche's opposition to Catalent's takeover, cost analysis of weight-loss drugs like Wegovy, U.S.
STAT1d
Pharmalittle: We’re reading about Novo targeting compounded obesity drugs, an Amgen ‘at risk’ launch, and more
Novo Nordisk asked the FDA to bar compounding pharmacies from making semaglutide, arguing it is too complex for the ...
BioPharma Dive1d
Merck acquires cancer drug startup; Elevidys ex-US sales rise
Yale spinout Modifi agreed to sell to Merck for $30 million upfront. Elsewhere, Sangamo plotted a much faster path to market ...
devdiscourse6d
Consumer and Labor Unions Oppose Novo's Catalent Acquisition
U.S. consumer groups and labor unions have called on the Federal Trade Commission to block Novo Holdings from acquiring ...